For the limitation of the study, we did not utilize the inhibitor of mTORC1 signaling pathway in the animal models, with which to investigate whether CREB3L4 could facilitate malignancy through activating mTORC1 pathway, or reduce the sensitivity of cancer cells to sorafenib. The gene discussed is CREB3L4; the disease is cancer.